Alpha Teknova Inc
NASDAQ:TKNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alpha Teknova Inc
NASDAQ:TKNO
|
US |
|
Danone SA
OTC:GPDNF
|
FR |
|
Westbridge Renewable Energy Corp.
OTC:WEGYD
|
CA |
|
Field Solutions Holdings Ltd
ASX:FSG
|
AU |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
US |
|
S
|
Seneca Foods Corp
NASDAQ:SENEB
|
US |
|
B
|
Baolong International Co Ltd
TWSE:1906
|
TW |
|
Wesco International Inc
NYSE:WCC
|
US |
|
Solocal Group SA
PAR:LOCAL
|
FR |
|
Kunwu Jiuding Investment Holdings Co Ltd
SSE:600053
|
CN |
|
Ming Fai International Holdings Ltd
HKEX:3828
|
HK |
|
Doright Co Ltd
SZSE:300950
|
CN |
|
C
|
Capex SA
BCBA:CAPX
|
AR |
|
C
|
Camanchaca SA
SGO:CAMANCHACA
|
CL |
|
ams OSRAM AG
OTC:AMSSY
|
AT |
|
C
|
City Lodge Hotels Ltd
XBER:C7P
|
ZA |
|
S
|
Sims Ltd
OTC:SMUPF
|
US |
|
Gigas Hosting SA
MAD:GIGA
|
ES |
|
Hefei Lifeon Pharmaceutical Co Ltd
SZSE:003020
|
CN |
|
D
|
Danieli & C Officine Meccaniche SpA
MIL:DAN
|
IT |
|
Linedata Services SA
PAR:LIN
|
FR |
|
N
|
NIFTY Lifestyle Co Ltd
TSE:4262
|
JP |
|
M
|
MPX Logistics International Tbk PT
IDX:MPXL
|
ID |
|
Rakus Co Ltd
TSE:3923
|
JP |
Alpha Teknova Inc
Alpha Teknova, Inc. manufactures cell culture media and supplements. The company is headquartered in Hollister, California and currently employs 231 full-time employees. The company went IPO on 2021-06-25. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Its processes enable it to manufacture and deliver custom, made-to-order products across all stages of development, including commercialization. The firm's processes are designed to handle as array of customer-requested inputs, which vary by volume, chemical formulation, quality specifications, container types, and transportation requirements, enabling use of its products across the scope of the life sciences market.
Alpha Teknova, Inc. manufactures cell culture media and supplements. The company is headquartered in Hollister, California and currently employs 231 full-time employees. The company went IPO on 2021-06-25. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Its processes enable it to manufacture and deliver custom, made-to-order products across all stages of development, including commercialization. The firm's processes are designed to handle as array of customer-requested inputs, which vary by volume, chemical formulation, quality specifications, container types, and transportation requirements, enabling use of its products across the scope of the life sciences market.
Revenue Growth: Teknova reported full year 2025 revenue of $40.5 million, up 7% year-over-year, with Q4 revenue up 8% to $10 million.
Margins: Gross margin improved to 33.2% for 2025, up from 19.2% in 2024, driven by higher revenue and manufacturing efficiency gains.
Cash Flow: Free cash outflow for 2025 was $9.8 million, beating guidance of less than $12 million and improving from $13.5 million in 2024.
2026 Guidance: Management guided 2026 revenue to $42–44 million (about 6% growth at the midpoint) and expects gross margin to be in the mid-30% range.
Strategic Investment: The company plans to invest an additional $2 million annually in commercial capabilities to accelerate growth in high-potential segments.
EBITDA Outlook: Teknova targets positive adjusted EBITDA by the end of 2027 when annualized revenue reaches $52–57 million.
Customer Base: Clinical customer count rose to 60 (up 25%), supporting over 70 therapies, with several Phase II or later.
End Market Trends: Management noted early signs of biotech funding recovery and expects potential revenue acceleration from Q4 2026 if funding persists.
